Department of Nuclear Medicine, Korea Cancer Centre Hospital, Korea Institute of Radiological and Medical Sciences, 75, Nowon-ro, Nowon-gu, Seoul, South Korea.
Division of Applied RI, Research Institute of Radiological & Medical Sciences, Korea Institutes of Radiological & Medical Sciences, Seoul, South Korea.
Eur J Nucl Med Mol Imaging. 2021 Jan;48(1):95-102. doi: 10.1007/s00259-020-04883-y. Epub 2020 May 26.
To evaluate the biodistribution of [F]Florastamin, a novel F-labelled positron emission tomography (PET) tracer for prostate-specific membrane antigen (PSMA) for the diagnosis of prostate cancer.
PET was performed for five healthy controls and 10 patients with prostate cancer at 0, 10, 30, 70, and 120 mins after injecting 370 MBq of [F]Florastamin. The maximum standardised uptake value (SUV) was evaluated in the primary tumour. The mean SUV (SUV) was evaluated in normal organs. Furthermore, the residence time was evaluated by assessing radioactivity in each organ. The internal radiation dosimetry was calculated using the OLINDA/EXM software.
The SUV in primary tumours increased with time. A favourable tumour to background ratio was also observed over time. Multiple lymph nodes and bone metastases were also evaluated and showed a similar pattern to SUV in the primary tumour. In one patient, a tiny lymph node metastasis was identified using [F]Florastamin PET, which was not observed using other modalities, and was histologically confirmed. The highest absorbed dose was observed in the kidney (0.062 ± 0.015 mGy/MBq), followed by the bladder (0.032 ± 0.013 mGy/MBq), liver (0.022 ± 0.006 mGy/MBq), and salivary gland (0.018 ± 0.006 mGy/MBq). The effective dose with a 370 MBq injection of [F]Florastamin was 1.81 mSv. No adverse events related to [F]Florastamin were reported.
We identified a novel PSMA-targeted PET ligand, [F]Florastamin, for imaging prostate cancer. [F]Florastamin showed a high SUV and relatively high tumour to background ratio in both primary tumour and metastatic lesions, which suggests its high sensitivity to detect tumours without any adverse events.
KCT0003924 registered at https://cris.nih.go.kr/ .
评估 [F]Florastamin 的生物分布，这是一种新型的 F 标记正电子发射断层扫描 (PET) 示踪剂，用于前列腺特异性膜抗原 (PSMA) 诊断前列腺癌。
对 5 名健康对照者和 10 名前列腺癌患者在注射 370MBq [F]Florastamin 后 0、10、30、70 和 120 分钟进行 PET 检查。评估原发肿瘤的最大标准化摄取值 (SUV)。评估正常器官的平均 SUV（SUV）。此外，通过评估每个器官的放射性来评估居留时间。使用 OLINDA/EXM 软件计算内部辐射剂量。
原发肿瘤的 SUV 随时间增加。随着时间的推移，肿瘤与背景的比值也很有利。还评估了多个淋巴结和骨转移，并显示出与原发肿瘤 SUV 相似的模式。在一名患者中，使用 [F]Florastamin PET 发现了一个小的淋巴结转移，而其他方式没有发现，并且通过组织学得到了证实。肾脏的吸收剂量最高（0.062±0.015 mGy/MBq），其次是膀胱（0.032±0.013 mGy/MBq）、肝脏（0.022±0.006 mGy/MBq）和唾液腺（0.018±0.006 mGy/MBq）。370MBq [F]Florastamin 注射的有效剂量为 1.81mSv。未报告与 [F]Florastamin 相关的不良反应事件。
我们发现了一种新型的 PSMA 靶向 PET 配体 [F]Florastamin，用于成像前列腺癌。[F]Florastamin 在原发肿瘤和转移病灶中均显示出高 SUV 和相对较高的肿瘤与背景比值，这表明其对肿瘤的高敏感性，且无任何不良反应。
在 https://cris.nih.go.kr/ 注册 KCT0003924。
